Allergan Lumigan Sales Aid Lacks Risk Info, Overstates Efficacy, FDA Says
Executive Summary
Allergan's dissemination of a sales aid for its glaucoma therapy Lumigan has prompted FDA's second letter to the company regarding product promotions in three months.